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Objective: Evaluate the efficacy of 0.8% arginine, potassium nitrate and sodium fluoride
mouthwashes on dentine hypersensitivity reduction.
Methods: Six week randomized, double blinded, two cell, parallel single centre clinical study
in the Dominican Republic; subjects were randomized into three treatment groups: mouth-
wash containing 0.8% arginine, PVM/MA copolymer, pyrophosphates, and 0.05% sodium
fluoride in an alcohol-free base (arginine); mouthwash containing 2.4% potassium nitrate
and 0.022% sodium fluoride (potassium nitrate); a control mouthwash containing 0.05%
sodium fluoride (negative control). Tactile and air-blast dentine hypersensitivity assess-
ments were conducted at baseline, thirty minutes post rinsing and two, four, and six weeks
of twice-daily product use. For treatment group comparisons, ANCOVA and post hoc
Tukey’s pair-wise comparisons (a = 0.05) were done.
Results: Seventy-five subjects were enrolled; 69 subjects completed the study. There were no
differences after thirty minutes of a single use, among the three groups with respect to mean
tactile and air blast hypersensitivity scores compared to potassium nitrate and negative
control mouthwashes ( p < 0.05). The arginine group presented a statistically significant
improvement in the mean tactile scores compared to potassium nitrate and negative control
groups after two, four, and six weeks ( p < 0.001) of product use; the arginine group showed a
statistically significant enhancement in air blast hypersensitivity mean scores compared to
potassium nitrate and negative control groups after two ( p = 0.001), four ( p < 0.001), and six
weeks ( p < 0.001) of product use.
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Conclusion: A mouthwash containing arginine provides a significant and superior reduction in
dentine hypersensitivity compared to potassium nitrate and a negative control mouthwash
after two weeks.
# 2012 Elsevier Ltd. 
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Dentine hypersensitivity is defined as a short, sharp pain
arising from exposed dentine in response to stimuli such as
thermal, evaporative, tactile, osmotic or chemical, and which
cannot be ascribed to any other form of dental defect
orpathology.1 Usually, this sharp pain occurs when the
surface of the root becomes exposed through gingival
recession uncovering the dentine tubule orifices on its
surface leading to a vital pulp.2 Previous studies have
reported that dentine hypersensitivity prevalence is ranged
3–73%, in adults.3
Several risk factors have been described previously in the
literature. For instance, the consumption of erosive dietary
foods and drinks, gingival recession, abrasion, and removal of
the tooth’s enamel, have been proposed as predisposing
factors for dentine hypersensitivity.4 Other risk factors are
age, chemical and/or physical forces such as instrumentation
of root surfaces during scaling procedures, and aggressive
tooth brushing.4 A transitory external stimuli such as a change
in temperature, air movement or a physical stimulus may
cause discomfort to the patient.5 The pathophysiological
mechanism of dentine hypersensitivity was explained by
Bra¨nnstro¨m’s hydrodynamic theory.6 This theory suggests
that external stimuli cause movement of the dentine fluid in
the tubules, resulting in a pressure change across dentine.
This stimulates intra-dental nerve response signals that are
ultimately interpreted by the brain as pain. Multiple agents
and products partially or completely block the dentine
tubules. The working mechanisms include: (1) creation of a
natural smear layer to occlude the tubules, (2) creation of an
artificial smear layer applying restorative resins or dentine
bond agents over the open tubules forming a thin film coating,
(3) creation of a layer of fine particles using a dentifrice with
fine abrasive particles that creates a precipitate in situ using
strontium and stannous fluoride, and (4) calcium phosphate-
based mineral formation in situ such as arginine containing
dental products to form a biological mineral within the
opening of the dentine tubules. Treatments to relieve dentine
hypersensitivity are based on two major approaches: the
occlusion of exposed and open tubules to block the hydrody-
namic mechanism of pain stimulation or the interruption of
the neural responses to a stimulus.7,8
Most desensitizing toothpastes contain potassium salts to
interrupt the neural response of pain caused by dental
hypersensitivity. In the United States, many of these
desensitizing toothpastes typically contain 5% potassium
nitrate (2% potassium ion). The clinical evidence suggests
that desensitizing toothpastes based on potassium are
effective. Nevertheless, others studies have reported that
these toothpastes are no more effective than regular fluoride
toothpastes.9 Gillam and coworkers10 have demonstrated
that the 3% potassium nitrate and sodium fluoride mouth-wash significantly reduces cervical dentine hypersensitivity
compared to the sodium fluoride mouthwash after two and
six weeks of use. Pereira et al.11 demonstrated that after two
weeks, there were no statistically significant differences
between the two groups using either method. At six weeks,
however, the 3% potassium nitrate and 0.2% sodium fluoride
mouthwash demonstrated a significant difference as com-
pared to the 0.2% sodium fluoride mouthwash using the cold
air technique.
Previous in vitro studies have demonstrated that dental
products containing 8% arginine and calcium carbonate seal
and plug dentine tubules.12,13 Other clinical studies have
demonstrated that the toothpaste containing 8% arginine,
calcium carbonate, and 1450 ppm fluoride provided statisti-
cally significant sensitivity relief after two, four, and eight
weeks.14,15 In addition, Docimo and colleagues have shown
statistically significant sensitivity relief for toothpastes with
8% arginine, calcium carbonate, and 1450 ppm fluoride
compared to a negative control toothpaste containing
1450 ppm fluoride.16 Furthermore, several clinical studies
have determined that when a toothpaste with 8% arginine,
calcium carbonate, and 1450 ppm fluoride is applied directly to
the affected tooth surface, an instant hypersensitivity effect
can be measured relative to a 5% potassium nitrate and
1450 ppm sodium fluoride toothpaste and to a 1450 ppm
sodium fluoridetoothpaste.17,18 Schiff et al. reported instant
sensitivity relief from direct application of a dentifrice with 8%
arginine, calcium carbonate, and 1450 ppm fluoride using a
fingertip versus a cotton swab19 both methods demonstrated a
statistically significant improvement in the mean tactile and
mean air blast hypersensitivity scores. When these topical
applications were followed by a one-week period of twice daily
brushing with the dentifrice, the sensitivity relief was
maintained.
Recently, a new mouthwash containing 0.8% arginine,
PVM/MA copolymer, pyrophosphates and 0.05% sodium
fluoride in an alcohol-free base was developed to address
dentine hypersensitivity.20,21 The aim of this study was to
determine if this new mouthwash, containing 0.8% arginine is
more efficient as compared to a 2.4% potassium nitrate and
0.022% sodium fluoride mouthwash and to a 0.05% sodium
fluoride mouthwash in reducing dentine hypersensitivity. Our
hypothesis is that an alcohol-free mouthwash 0.8% arginine
reduces dentine hypersensitivity compared to a 2.4% potassi-
um nitrate and 0.022% sodium fluoride mouthwash and to a
0.05% sodium fluoride mouthwash.
2. Materials and methods
This randomized clinical double-blinded, single centre, two
cell clinical study was conducted to assess three parallel
treatment groups.
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based on a standard deviation (SD), for the response measure
tactile sensitivity (or air blast) of 3.34 (or 0.31), a significance
level of a = 0.05, a 10% attrition rate and an 80% power level.
The study was powered to detect a minimal statistically
significant difference between the study means of 20%.
Prospective study subjects reported to a private clinical facility
in Santo Domingo, Dominican Republic, having refrained from
all oral hygiene procedures, from chewing gum for eight
hours, and from eating and drinking for four hours prior to
their examination.
Inclusion and exclusion criteria:
i. Subjects ranged in age from 18 to 70 (inclusive), and were
in generally good health.
ii. Subjects had at least two hypersensitive teeth, anterior to
the molars, that demonstrated cervical erosion/abrasion
or gingival recession; and presented a tactile sensitivity
stimuli score of 10–50 g of force (Yeaple Probe), and an air
blast stimuli score of 2 or 3 (Schiff Cold Air Sensitivity
Scale) at the baseline examination.
iii. Subjects were available to participate for the duration of
the six-week study and willing to sign an informed
consent form.
iv. Subjects were excluded from the study if they had gross
oral pathology, chronic disease, advanced periodontal
disease, had undergone treatment for periodontal disease
(within the last 12 months), or had hypersensitive teeth
with mobility greater than one. Subjects with teeth that
had extensive/defective restorations (including prosthetic
crowns), suspected pulpitis, caries, cracked enamel or that
were used as abutments for removable partial dentures.
v. Subjects that were taking anticonvulsants, antihista-
mines, antidepressants, sedatives, tranquilizers, anti-
inflammatory drugs or daily analgesics within one month
prior to the start of the study or, who started taking these
drugs during the course of the study were excluded from
participation.
vi. Pregnant or lactating women, individuals who were
participating in any other clinical study or who had
participated in a desensitizing dentifrice study, or who
had used a desensitizing dentifrice within the last three
months, were not allowed to participate in the study.
vii. Subjects with a history of allergy to the test products, or
allergies to oral care/personal care consumer products or
their ingredients, or subjects with existing medical
conditions that precluded them from eating and drinking
for periods up to four hours, were also excluded from the
study.
The first seventy-five (75) prospective subjects who met the
inclusion/exclusion criteria and signed an informed consent
form received a baseline tactile hypersensitivity and an air
blast hypersensitivity evaluation, along with an oral soft and
hard tissue assessment. Qualifying subjects were then
sequentially randomized using a list of random numbers,
and assigned to one of three study treatment: (1) mouthwash
(‘‘arginine’’) containing 0.8% arginine, polyvinylmethylether/
maleic acid (PVM/MA) copolymer, pyrophosphates, and 0.05%
sodium fluoride in an alcohol-free base, (2) commercialmouthwash (‘‘potassium nitrate’’) containing 2.4% potassium
nitrate and 0.022% sodium fluoride, and (3) a mouthwash
(‘‘negative control’’) containing 0.05% sodium fluoride.
Mouthwashes were over-wrapped to maintain the blinding
of the study participants, examiners and all study personnel.
Site personnel not involved in the clinical evaluations
distributed all test products in sealed opaque bags in an area
separate from the examination room. The three products were
letter coded.
After baseline evaluation and product assignment, subjects
were instructed to brush and rinse with their assigned product
as per the instructions provided. Subjects were instructed to
brush their teeth and to swish 20 ml of their assigned rinse
between their teeth for 30 s, and then to spit it out. They were
then instructed to refrain from eating or drinking for 30 min.
After 30 min, subjects were evaluated for dentine hypersensi-
tivity following the same procedures employed at baseline.
After this evaluation, subjects took their assigned product for
unsupervised home use for a total of six weeks. At-home
instructions consisted of brushing the teeth for one minute,
twice daily, using only the toothpaste containing 1450 ppm
fluoride and the soft toothbrush provided. After brushing,
participants rinsed with water then rinsed for thirty seconds
with 20 ml of their assigned mouthwash. Subjects were
advised to refrain from any other oral hygiene procedures
throughout the duration of the study. In addition, subjects
were also instructed to refrain from chewing gum for eight
hours and from eating and drinking for four hours prior to
their follow-up hypersensitivity evaluations. There were no
other restrictions regarding diet or smoking habits during the
course of the study.
Subsequent evaluations were conducted after two, four
and six weeks of product use. All examinations were
performed by the same trained and standardized dental
examiner, using the same procedures as employed at baseline.
Oral soft and hard tissue assessments, as well as, tactile and
air blast hypersensitivity were conducted. Subjects were
interviewed with respect to the presence of adverse events
and the use of concomitant medications.
3. Clinical scoring procedures
3.1. Tactile hypersensitivity assessment
Tactile hypersensitivity was assessed by use of the Model 200A
Electronic Force Sensing Probe developed by Yeaple Research
of Pittsford, NY. A #19 explorer tip, at a pre-set force measured
in grams, was employed to measure dental hypersentivity.
Teeth were evaluated for tactile hypersensitivity in the
following manner:
(1) The subject was instructed to respond at the point where
he or she first experienced discomfort.
(2) The explorer tip of the probe was applied to the buccal
surface of each hypersensitive tooth at the CEJ.
(3) The explorer tip was stroked perpendicular to the tooth
beginning at a pre-set force of 10 g (0.01 kg) and increased
by 10 g (0.01 kg) increments until the subject experienced
discomfort, or until 50 g (0.05 kg) of force was applied.
Table 1 – Summary of age and gender: for subjects who
completed the six-week clinical study.
Treatment Age (years)a Gender
Mean (range) Malea
n (%)
Femalea
n (%)
Total
N
Arginine 32 (21–47) 12 (50.0) 12 (50.0) 24
Potassium nitrate 33 (21–59) 19 (79.1) 5 (20.9) 24
Negative control 33 (21–48) 11 (52.4) 10 (47.6) 21
a No statistically significant difference was indicated between the
three treatment groups with respect to either gender or age
( p > 0.05).
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measured on the two baseline-designated study teeth.
3.2. Air blast hypersensitivity assessment
Teeth were evaluated for air blast hypersensitivity in the
following manner:
(1) The sensitive tooth was isolated from the adjacent teeth
(mesial and distal) by the placement of the examiner’s
fingers over the adjacent teeth.
(2) Air was delivered from a standard dental unit air syringe at
60 psi (4.22 kgf/cm2)  5 psi (0.35 kgf/cm2) and 70 8F
(21)  3 8F (16). The air was directed at the exposed
buccal surface of the hypersensitive tooth for one second
from a distance of approximately 1 cm.
(3) The Schiff Cold Air Sensitivity Scale19 was used to assess
subject response to this stimulus.
This scale was scored as follows:
0 – Subject did not respond to air stimulus.
1 – Subject responded to air stimulus but did not request
discontinuation of stimulus.
2 – Subject responded to air stimulus and requested
discontinuation or moved from stimulus.
3 – Subject responded to air stimulus, considered stimulus
to be painful and requested discontinuation of the
stimulus.
3.3. Oral soft and hard tissue assessment
The dental examiner visually examined the oral cavity and
peri-oral area using a dental light and dental mirror. This
examination included an evaluation of the soft and hard
palate, gingival mucosa, buccal mucosa, mucogingival fold
areas, tongue, sublingual and submandibular areas, salivary
glands, and the tonsilar and pharyngeal areas.
3.4. Adverse events
Adverse events were obtained from an interview with the
subjects and a dental examination by the investigator.
4. Statistical methods
Statistical analyses were performed separately for the tactile
and air blast hypersensitivity assessments. Comparisons of
the treatment groups with respect to gender were performed
using a chi-square analysis, and for age an analysis of
variance (ANOVA). Comparisons of the treatment groups with
respect to baseline-adjusted tactile and air blast hypersensi-
tivity mean scores at the follow-up examinations were
performed using an analysis of covariance (ANCOVA). A post
hoc Tukey’s multiple comparison test was performed on all
pair-wise means, when the ANCOVA showed a statistical
significant difference among the treatment groups. All
statistical tests of hypotheses were two sided, and employed
a level of significance of a = 0.05.5. Results
During the second week of September, 2009 seventy-five (75)
subjects were enrolled and were randomly assigned to three
study groups of 25 participants. Sixty-nine (69) subjects
complied with the protocol, and completed the six-week
clinical study on the final visit during the third week of
October, 2009 (Fig. 1). A summary of the gender and age of
those subjects who completed the study is presented in Table
1. The treatment groups did not differ significantly with
respect to either gender ( p > 0.05) or age ( p > 0.05). There were
three adverse events reported to be unrelated to product use.
Additionally, there were three subjects who did not complete
the study due to non-protocol compliance.
Table 2 depicts the mean tactile hypersensitivity scores for
each of the treatment groups during the study period. The
mean tactile hypersensitivity scores at baseline among the
treatment groups were similar ( p > 0.05). However, the
arginine group exhibited a statistically significant improve-
ment in baseline-adjusted mean tactile hypersensitivity
scores relative to the potassium nitrate group and the negative
control group of 86.3% ( p < 0.001) and 125.3% ( p < 0.001),
respectively after two weeks of product use. Furthermore, the
arginine group showed statistically significant improvement
in baseline-adjusted mean tactile hypersensitivity scores as
compared to the potassium nitrate group and negative control
group of 100.7% ( p < 0.001) and 172.9% ( p < 0.001), respectively
after four weeks of use. After six weeks of use, the arginine
group presented a statistically significant improvement in
baseline-adjusted mean tactile hypersensitivity scores com-
pared to the potassium nitrate group and negative control
group of 86.2% ( p < 0.001) and 232.6% ( p < 0.001), respectively.
There were no statistically significant differences between the
potassium nitrate group and negative control group in
baseline-adjusted mean tactile hypersensitivity score after
thirty minutes ( p = 0.72); and two ( p = 0.632) and four
( p = 0.280) weeks of product use. However, the potassium
nitrate group exhibited a statistically significant reduction in
baseline-adjusted mean relative to the negative control group
of 78.7% ( p = 0.005) after 6 weeks.
Table 3 represents a summary of the mean air blast
hypersensitivity scores for each of the treatment groups
during study period. The mean air blast hypersensitivity
scores at baseline among the treatment groups were
similar ( p > 0.05). After 30 min of the initial rinsing, there
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Fig. 1 – Patient flowchart.
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Table 2 – Summary of the tactile hypersensitivity scores for subjects who completed the six week study.
Treatment Baselinea
(mean  SD)
30 min
(mean  SD)
% difference
30 minb
2 weeks
(mean  SD)
% difference
2 weeks
4 weeks
(mean  SD)
% difference
4 weeks
6 weeks
(mean  SD)
% difference
6 weeks
N
Potassium
nitrate
Negative
control
Potassium
nitrate
Negative
control
Potassium
nitrate
Negative
control
Arginine 10.83  2.41 11.13  1.43 2.2 ( p = 0.826) 25.32  8.58 86.3
( p < 0.001)
125.3
( p < 0.001)
34.36  9.80 100.7
( p < 0.001)
172.9
( p < 0.001)
39.58  10.18 86.2
( p < 0.001)
232.6
( p < 0.001)
24
Potassium
nitrate
10.42  1.41 11.38  1.43 1.7 ( p = 0.898) 13.59  8.60 – 20.9
( p = 0.632)
17.12  9.83 – 36.0
( p = 0.280)
21.26  10.21 – 78.7
( p = 0.009)
24
Negative
control
10.95  3.01 10.94  1.43 4.0 ( p = 00.574) 11.24  8.59 – – 12.59  9.81 – – 11.90  10.19 – – 21
a Treatments are not statistically significantly different from each other at baseline ( p > 0.05).
b Arginine vs. potassium nitrate and negative control mouthwash groups.
Table 3 – Summary of the air blast hypersensitivity scores for subjects who completed the six-week study.
Treatment Baselinea
(mean  SD)
30 min
(mean  SD)
% difference
30 minb
2 weeks
(mean  SD)
% difference
2 weeks
4 weeks
(mean  SD)
% difference
4 weeks
6 week
(mean  SD)
% difference
6 weeks
N
Potassium
nitrate
Negative
control
Potassium
nitrate
Negative
control
Potassium
nitrate
Negative
control
Arginine 2.31  0.38 1.90  0.52 15.9 ( p = 0.053) 0.98  0.55 37.6
( p = 0.001)
51.2
( p < 0.001)
0.44  0.60 65.9
( p < 0.001)
76.6
( p < 0.001)
0.35  0.53 68.2
( p < 0.001)
80.4
( p < 0.001)
24
Potassium
nitrate
2.31  0.55 2.26  0.52 10.8 ( p = 0.316) 1.57  0.55 – 21.9
( p = 0.025)
1.29  0.60 – 31.4
( p = 0.005)
1.10  0.53 – 38.5
( p < 0.001)
24
Negative
control
2.50  0.47 2.13  0.52 6.1 ( p = 00.702) 2.01  0.55 – – 1.88  0.60 – – 1.79  0.53 – – 21
a Treatments are not statistically significantly different from each other at baseline.
b Arginine vs. potassium nitrate and negative control mouthwash groups.
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adjusted mean air blast scores, arginine vs. potassium
( p = 0.053) and negative control ( p = 0.316). Nevertheless, the
arginine group exhibited a statistically significant reduction in
baseline-adjusted air blast mean hypersensitivity scores as
compared to the potassium nitrate group and the negative
control group of 37.6% ( p = 0.001) and 51.2% ( p < 0.001),
respectively after two weeks of product use. In addition, the
potassium nitrate group exhibited a statistically significant
reduction in baseline-adjusted air blast hypersensitivity mean
scores relative to the negative control group of 21.9% ( p = 0.025),
after two weeks. After four weeks, the arginine group exhibited
a statistically significant reduction in baseline-adjusted air blast
hypersensitivity mean scores, as compared to the potassium
nitrate group and the negative control group of 65.9%
( p < 0.001) and 76.6% ( p < 0.001), respectively. Also, the
potassium nitrate group exhibited a statistically significant
reduction in baseline-adjusted mean air blast hypersensi-
tivity mean scores when compared to the negative control
group of 31.4% ( p = 0.005) after four weeks. After six weeks
of product use, the arginine group exhibited a statistically
significant reduction in baseline-adjusted air blast hyper-
sensitivity mean scores as compared to the potassium
nitrate group and the negative control group of 68.2%
( p < 0.001) and 80.4% ( p < 0.001), respectively. Further-
more, the potassium nitrate group exhibited a statistically
significant reduction in baseline-adjusted mean air blast
hypersensitivity relative to the negative control group of
38.5% ( p < 0.001), after six weeks.
6. Discussion
The aim of this randomized clinical trial was to evaluate the
efficacy on dentine hypersensitivity reduction of a mouth-
wash containing 0.8% arginine and 0.05% sodium fluoride
compared to a mouthwash containing 2.4% potassium nitrate
and 0.022% sodium fluoride and a negative control mouth-
wash containing 0.05% sodium fluoride through a six-week
period.
Our hypothesis was that an alcohol-free mouthwash using
arginine is more effective in reducing dentine hypersensitivity
compared to a 2.4% potassium nitrate and 0.022% sodium
fluoride and to 0.05% sodium fluoride mouthwashes. Indeed,
the participants assigned to the arginine mouthwash group
showed statistically significant improvements in tactile and
air blast dentine hypersensitivity relative to the potassium
nitrate mouthwash group and to the negative control
mouthwash group after two, four and six weeks of product
use. However, the treatment groups did not show efficacy on
dentine hypersensitivity reduction thirty minutes after the
initial rinsing.
In this study, the participants in the arginine mouthwash
group presented a faster and a greater magnitude of reduction
in dentine hypersensitivity using tactile and air blast
measurements compared to potassium nitrate and negative
control groups. We also observed a reduction in dentine
hypersensitivity using potassium nitrate mouthwash com-
pared to negative control group, more evident in air blast
measurement.To our knowledge this is the first clinical trial reporting on
the efficacy of a mouthwash containing arginine, PVM/MA
copolymer, pyrophosphates, and sodium fluoride compared to
potassium nitrate and negative control mouthwashes. How-
ever, our results are consistent with findings in several clinical
studies that toothpaste containing 8% arginine, calcium
carbonate, and 1450 ppm fluoride provides a statistically
significant relief in dentine hypersensitivity after two, four,
and eight weeks of product use.14,15,22,23
Instant hypersensitivity relief has been reported using
an 8% arginine, calcium carbonate and fluoride toothpaste
compared to a 5% potassium nitrate and 1450 ppm sodium
fluoride toothpaste, and to 1450 ppm sodium fluoride
toothpaste in other studies17,18; however, it was not
observed in the present study. This lack of hypersensitiv-
ity reduction might be explained by a lower concentration
of arginine in the mouthwash compared to the toothpaste, or by
differences in application method. Gillam and coworkers10have
observed statistically significant differences between a 3%
potassium nitrate and sodium fluoride mouthwash and a
sodium fluoride mouthwash after two and six weeks of
treatment using air blast hypersensitivity mean scores. Pereira
et al.,11 have observed a statistically significant improvement in
dentine hypersensitivity for a 3% potassium nitrate and 0.2%
sodium fluoride mouthwash compared to a 0.2% sodium
fluoride mouthwash only at six weeks using the cold air
technique. These results were consistent with those obtained in
our study.
The mechanisms of action of an arginine containing
mouthwash provide a calcium phosphate-based mineral
formation within the opening of the dentine tubules. Our
results support the hypothesis that this mechanism is more
effective in the reduction of dentine hypersensitivity than the
creation of a layer of fine particles using a dentifrice with fine
abrasive particles that creates a precipitate in situ using
potassium salts.
7. Conclusion
Our results support the hypothesis that an alcohol-free
mouthwash using 0.8% arginine mouthwash provides a
significant and superior reduction in dentine hypersensitivity
after two, four and six weeks of product use compared to
mouthwash containing 2.4% potassium nitrate and 0.022%
sodium fluoride and to a control mouthwash containing 0.05%
sodium fluoride.
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